MedTrace Logo

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy

NCT05103306 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-07-20

No results posted yet for this study

Summary

This study aimed to evaluate the long-term effectiveness and safety of the empagliflozin as add-on thearpy compared to basal insulin-based antidiabetic agents (OADs) combination therapy in patients with type 2 diabetes inadequately controlled on triple OADs in a real clinical practice.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Empagliflozin 25 MG

Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor

DRUG

INS

Basal insulin add on the background OADs

Sponsors & Collaborators

  • Chungbuk National University Hospital

    lead OTHER

Principal Investigators

  • Eu Jeong Ku, MD, PhD · Chungbuk National University Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2022-12-31
Completion
2022-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05103306 on ClinicalTrials.gov